Persongen Biotherapeutics (suzhou) Co., Ltd.

This early study tests a new treatment called LV009 injection in 10 adults with certain blood cancers (non-Hodgkin lymphoma or acute lymphoblastic leukemia) that have returned or not responded to standard therapy. The main goal is to check if the treatment is safe. Participants r…

This early-phase study tests a new treatment called LV009 injection for people with certain blood cancers (non-Hodgkin lymphoma and acute lymphoblastic leukemia) that have not responded to standard therapy or have returned. The treatment uses the patient's own immune cells, modif…

This early-phase study tests a new treatment called UTAA07 for adults with CD7-positive blood cancers that have come back or not responded to standard therapy. The main goals are to check safety and find the right dose. About 15 participants will receive the treatment and be clos…

This study tests an experimental treatment called PA3-17 for people with a type of blood cancer (T-lymphoblastic leukemia/lymphoma) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…